US commercial plans increase choice of biosimilar and originator products; market net prices decrease
STAT
Medicare’s new transitional coverage of emerging technologies program doesn’t go far enough
Value in Health
The health benefits, costs, and cost-effectiveness of ultraorphan drugs
Health Affairs Forefront
Improving how CMS defines “unmet medical need” under the IRA
Clinical Therapeutics
Balancing evidence and need: variation in US commercial payer coverage of Esketamine
Health Affairs Scholar
Biosimilar underutilization alone does not foretell a broken biologics market
Health Affairs Forefront
In remembrance of Gail Wilensky
Health Affairs Forefront
Prioritizing services and procedures for value assessment
Health Affairs Scholar
Towards a coordinated approach for managing accelerated patient access to potentially beneficial medicines: reporting the perspectives of a multi-stakeholder, international workshop
